Impact of COVID-19 on Business and Performance
First written in FY2020. 5 of 11 entries say "Restated". Latest entry: FY2024.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
- FY2024ReframedAnnual report
「The spread of infectious diseases with a high level of danger in terms of transmissibility and severity if contracted, as well as the implementation of strict disease-control policies, may interrupt business activities, including through the suspension of raw-material supplies and factory production, and may affect performance.」
The Company reorganized the risk description from a specific COVID-19 risk to a general infectious-disease risk, including prolonged spread and supply or production stoppages caused by disease-control measures. - FY2023-Q3RestatedAnnual report
「We have continued our business activities while thoroughly implementing measures to prevent COVID-19 infection.」
The Company is conducting business activities while continuing to thoroughly implement measures to prevent COVID-19 infection. It states that there has been no material change in the infection risk itself. - FY2023-Q1RestatedAnnual report
「We have continued our business activities while thoroughly implementing measures to prevent COVID-19 infection.」
The Company is conducting business activities while continuing to thoroughly implement measures to prevent COVID-19 infection. It states that there has been no material change in the infection risk itself. - FY2022RestatedAnnual report
「The economic outlook remains highly uncertain because the spread of COVID-19 is still continuing, and the timing of its containment and the impact of its spread cannot yet be forecast.」
The continued spread of COVID-19 and uncertainty over the timing of its containment and its impact on performance continue to be described as risks. - FY2022-Q2RestatedAnnual report
「The spread of COVID-19 may affect the Company's financial position and business performance.」
The Company continues to disclose the possibility that COVID-19 may affect its financial position and business performance. While the adverse impact of the decline caused by factory suspensions and other factors in the same period of the previous year has been eliminated, the Company states that there has been no material change in the infection risk itself. - FY2022-Q1RestatedAnnual report
「The spread of COVID-19 may affect the Company's financial position and business performance.」
The Company continues to disclose the possibility that COVID-19 may affect its financial position and business performance. While the adverse impact of the decline caused by factory suspensions and other factors in the same period of the previous year has been eliminated, the Company states that there has been no material change in the infection risk itself. - FY2021MaterialisedAnnual report
「Although we worked to restrain selling expenses, including advertising expenses, and reduce other administrative expenses, these measures were insufficient to offset the decline in net sales through the second quarter of the consolidated fiscal year. Operating profit was ¥1,932 million, down 33.8% year on year, ordinary profit was ¥2,005 million, down 33.3%, and net profit attributable to owners of the parent was ¥840 million, down 45.5%.」
The impact of COVID-19, including factory suspensions and store closures, became apparent for the full fiscal year, resulting in lower revenue and lower profit. Meanwhile, the Company explained that the impact had begun to ease from the third quarter onward. - FY2021-Q3MaterialisedAnnual report
「In terms of business performance, the company was significantly affected through the cumulative second quarter by the temporary suspension of production plants in the Philippines and the closure of some domestic stores due to the spread of COVID-19. In the third quarter under review, however, the impact was easing, and both net sales and profits exceeded the levels of the same quarter of the previous year.」
The suspension of factory operations and closure of stores caused by COVID-19, together with its impact on performance, continued through the cumulative second quarter, while the Company stated that the impact was beginning to ease in the third quarter. - FY2021-Q2MaterialisedAnnual report
「However, due to the temporary suspension of production plants in the Philippines and the closure of some domestic stores resulting from the spread of COVID-19, net sales for the cumulative second quarter under review were ¥14,793 million, down 26.5% year on year.」
The impact of COVID-19 on business and performance became apparent through the cumulative second quarter, resulting in factory suspensions, store closures, a 26.5% decline in net sales and an operating loss of ¥592 million, among other effects. - FY2021-Q1MaterialisedAnnual report
「Net sales for the cumulative first quarter under review were ¥5,414 million, down 37.0% year on year, due to the temporary suspension of production plants in the Philippines and the closure of some domestic stores resulting from the spread of COVID-19.」
Regarding COVID-19, which was described as an independent risk in the previous fiscal year, actual impacts included a temporary suspension of operations at the Philippine factory, closures of domestic stores, a 37.0% decline in net sales and an operating loss. - FY2020First statedAnnual report
「Large-scale disasters such as pandemics may pose a risk of having a material impact on the Group's performance. Even if a large-scale disaster such as a pandemic occurs, we are considering a business continuity plan to fulfill our social responsibilities by maintaining our production, logistics, sales and other functions at a certain level and continuing to provide products and services to customers. In light of the current impact of COVID-19, we have formulated and implemented basic policies and operating guidelines.」
Following the global spread of COVID-19, the Company independently described for the first time the risk of a pandemic's impact on performance and the consideration and implementation of basic policies, operating guidelines and a BCP.